Wound Healing Clinical Trial
Official title:
A Prospective Single Center Within Subject Controlled Observational Study to Evaluate Apligraf(R) in Nonhealing Wounds of Subjects With Epidermolysis Bullosa
Verified date | March 2015 |
Source | University Hospital, Basel, Switzerland |
Contact | n/a |
Is FDA regulated | No |
Health authority | Switzerland: Ethikkommission |
Study type | Interventional |
Epidermolysis Bullosa (EB) is a very rare disease, with a severe impact on the life of the patient and the caregiver. Epidermolysis Bullosa (EB) comprises a group of genetically determined skin fragility disorders characterized by blistering of the skin and mucosae following mild mechanical trauma. There is no specific proven treatment for any form of EB, and the mainstay of clinical management is based on protection and avoidance of provoking factors. Chronic nonhealing erosions and ulcers have been treated with conventional split-thickness skin grafts. Alternatively some patients may benefit from the use of autologous or allogeneic cultured keratinocyte grafts.
Status | Terminated |
Enrollment | 3 |
Est. completion date | January 2015 |
Est. primary completion date | January 2015 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 2 Years to 65 Years |
Eligibility |
Inclusion Criteria: 1. Subject is between 2 and 65 years of age. 2. Subject with clinical confirmed diagnosis of EB. 3. Subject has at least two lesions, if in a situation with two non-adjacent EB lesions, at least 4 cm apart. 4. Subject with EB lesions at least 2 cm2 present for at least 3weeks. For the purposes of this study, a lesion is defined as a wound resulting from a post blister erosion. 5. Subject who is a female of child-bearing potential (females >10 years of age) must have a documented negative urine or serum pregnancy test. Sexually active females must be practicing a medically proven form of contraception during the course of the study period. 6. Subject or legal guardian must have read, understood and signed an institutional review board (IRB) approved Informed Consent Form or Assent Form. 7. Subject and/or legal guardian must be able and willing to follow study procedures and instructions. Exclusion Criteria: - 1. Subject whose lesion has healed 20% or greater in area from post debridement (if applicable) Baseline Screen (Visit 1) to post debridement Day 0 (Visit 2) as determined by wound tracings. 2. Subject with uncontrolled diabetes mellitus (glycosylated HbA1C > 10%), cancer (biopsy confirmed active malignancy), or positive HIV test. 3. Subject is a child (<18 years of age) who is currently receiving or has received oral steroid therapy exceeding a total daily dose of 0.5mg/kg for more than two weeks, radiation or other immuno-suppressive therapy which would interfere with wound healing within the past four weeks. 4. Subject is an adult (>18 years of age) who is currently receiving or has received chronic high dose steroid therapy exceeding a total daily dose of 20mg for more than two weeks, radiation or other immuno-suppressive therapy which would interfere with wound healing within the past four weeks. 5. Subject who is currently on or has received topical steroidal therapy within 30 days before screening. Inhaled steroids are allowed. 6. Subject with the presence of acute infections in the areas intended for treatment. 7. Known hypersensitivity to bovine collagen or to the components of the Apligraf agarose shipping medium. 8. Subject who is lactating or pregnant (hCG positive as determined by lab testing). 9. Subject enrolled in any wound or investigational device study for any disease within the past four weeks. 10. Subject who has received an investigational drug or biological treatment within three months. 11. Subject with a history of alcohol or substance abuse within the previous year, which could interfere with study compliance such as inability to attend scheduled study visits or compliance with home dressing changes. 12. Subject who, in the opinion of the investigator, for any reason other than those listed above, will not be able to complete the study per protocol. |
Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Switzerland | University Hospital Basel | Basel |
Lead Sponsor | Collaborator |
---|---|
University Hospital, Basel, Switzerland | Organogenesis |
Switzerland,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Pain | Reduction of intensity of pain | Study duration | No |
Primary | Proportion of wounds | Proportion of wounds first achieving 100 % epithelialization of tissue with the absence of drainage (i.e. complete wound closure) through study week 12. | through study week 12 | No |
Secondary | Time | Time until 100 % epithelialization of wound tissue with the absence of drainage (i.e.complete wound closure). | until 100% epithelialization | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05045183 -
A Study to Assess Wound Healing Efficacies of Different Clean, Treat, and Protect Wound Care Regimens Compared to Standard of Care and Untreated
|
N/A | |
Enrolling by invitation |
NCT04613336 -
Efficacy of Topical Heparin Spray on Donor Site Wound Healing Time Compared to Conventional Dressing Among Patients Undergoing Split Thickness Skin Grafting
|
||
Recruiting |
NCT02241811 -
Wound Treatment With 3% Sodium Pentaborate Pentahydrate
|
Phase 1 | |
Completed |
NCT02797899 -
Effect of PRF Palatal Bandage on Pain Scores and Wound Healing After Free Gingival Graft
|
N/A | |
Completed |
NCT01227759 -
Tyrosur® Gel-Investigation on Wound Healing Efficacy
|
Phase 2 | |
Completed |
NCT01061502 -
Efficacy Study of a Bioelectric Dressing to Treat Skin Graft Donor Site Wounds
|
Phase 1/Phase 2 | |
Completed |
NCT00736593 -
A Study Evaluating Nexagon™ in the Treatment of Skin Wounds.
|
Phase 1 | |
Completed |
NCT00977951 -
Genomic Changes Associated With the Use of Intradermal Avotermin (Juvista) in Small Wounds in Healthy Male Subjects
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT03872544 -
Short Term Status of Free Dermal Fat Autografts for Complex Craniofacial Wounds
|
||
Enrolling by invitation |
NCT03880188 -
Long Term Status of Free Dermal Fat Autografts for Complex Craniofacial Wounds
|
||
Recruiting |
NCT05191082 -
Manufacturing, Characterization and Evaluation of the Effect of Silk Fibroin Membranes, Loaded or Not With Neurotensins on Open Wounds in the Palate
|
N/A | |
Enrolling by invitation |
NCT05942235 -
The Use of Microlearning in Nursing Education
|
||
Completed |
NCT03433820 -
Wound Healing in Healthy Volunteers
|
N/A | |
Withdrawn |
NCT02383992 -
Postoperative Care of Sutured Wounds
|
N/A | |
Recruiting |
NCT02034539 -
VADOplex Critical Limb Ischemia Study
|
Phase 2/Phase 3 | |
Recruiting |
NCT01680042 -
Clinical Effect of Phenytoin Mucoadhesive Paste on Wound Healing After Oral Biopsy
|
Phase 1 | |
Completed |
NCT01734317 -
An Open Single-centre Investigation Evaluating Efficacy in Second Degree Partial Thickness Burns Using a Silicone Contact Layer Containing Silver.
|
N/A | |
Withdrawn |
NCT01008111 -
Wound Healing of Incisional Wounds for Bilateral Hernia Repair
|
Phase 1 | |
Completed |
NCT01115218 -
The Influence of Anterior Chamber Fluid Mediators on the Success Rate of Trabeculectomy
|
||
Terminated |
NCT00177060 -
Topical Hydromorphone for Wound Healing
|
Phase 1/Phase 2 |